Fidson stake held by Nigerian tycoon Fidelis Ayebae rises by $2.4 million

Key Points

• Fidelis Ayebae’s 33.1% stake in Fidson Healthcare has surged by $2.4 million in 29 days, reaching a total value of over $13 million.
• Fidson Healthcare shares have risen 21.88% since May 5, pushing the company’s market cap to nearly $32 million and boosting investor returns.
• Year-to-date, Fidson stock is up 79.68%, delivering strong returns and signaling growing investor confidence in the pharmaceutical firm.

Nigerian pharmaceutical mogul Fidelis Ayebae has recorded a significant increase in the market value of his stake in Fidson Healthcare Plc, with his stake in the pharmaceutical company scoring a paper gain of $2.4 million driven by the sustained rally in the company’s shares on the Nigerian Exchange (NGX).

Ayebae, a former banker who made his mark in Nigeria’s pharmaceutical sector, holds a 33.1-percent stake in Fidson Healthcare, equivalent to 759.6 million ordinary shares. This position places him among the wealthiest individual investors on the NGX. Over the past 30 days, his stake has surged by N3.8 billion ($2.4 million), propelling the market value of his stake above $13 million.

Fidson share surge adds $2.4 million to Ayebae’s wealth

Founded in 1995 by Fidelis Ayebae, Fidson Healthcare has grown into one of Africa’s leading pharmaceutical companies, manufacturing and distributing a wide range of pharmaceutical products.     

Since May 5, Fidson’s shares on the NGX have climbed by 21.88 percent, rising from N22.85 ($0.0144) to N27.85 ($0.0176). This rally has propelled the company’s market capitalization to nearly $32 million, delivering substantial returns to shareholders—including Fidelis Ayebae.

As a result of the share price increase, the market value of Ayebae’s 33.1-percent stake has risen by N3.8 billion ($2.4 million), growing from N17.36 billion ($10.95 million) on May 5 to N21.16 billion ($13.35 million).  This $2.4-million gain adds to the $3.08 million increase in his wealth recorded between Jan. 1 and May 2, cementing Ayebae’s spot among Africa’s most affluent pharmaceutical moguls.

Year-to-date performance

Fidson Healthcare Plc has delivered remarkable returns for investors in 2025, with its share price surging by 79.68 percent year-to-date. This performance underscores growing investor confidence in the pharmaceutical firm amid strong financials and sector tailwinds.

To put the rally into perspective, A $100,000 investment in the company’s shares at the start of 2025 would now be worth $179,680, reflecting a substantial gain of $79,680 in just five months—a testament to the company’s robust market momentum and value creation for shareholders.